The global healthcare landscape is undergoing a paradigm shift towards precision medicine, where Polymerase Chain Reaction (PCR) technology serves as the gold standard. As a leading manufacturer in China, we recognize that PCR diagnostic tools are no longer just laboratory instruments; they are critical infrastructure for public health, oncology, and infectious disease management. The demand for High-Throughput PCR Systems and Point-of-Care (POCT) solutions is skyrocketing as clinical laboratories seek to balance speed, accuracy, and operational cost-effectiveness.
In the current industrial context, China’s biotech manufacturing sector—anchored in hubs like Shenzhen—has evolved from a mass-producer into a global innovation leader. By integrating AI-driven analysis and automated sample processing, we provide "Information Gain" to clinicians, enabling them to derive deeper insights from biological data than ever before.
Shenzhen BioX Medical Co., Ltd. is a professional manufacturer specializing in molecular diagnostic analysis systems, genetic testing solutions, and clinical laboratory equipment. Established in 2017, the company is headquartered in Shenzhen, China, a leading center for biotechnology innovation, medical device development, and advanced manufacturing.
With a modern manufacturing facility covering more than 9,000 square meters and a workforce of over 200 employees, BioX Medical is dedicated to the research, development, production, and supply of molecular diagnostic technologies for clinical laboratories, hospitals, research institutions, public health organizations, and biotechnology companies worldwide.
The company's product portfolio includes molecular diagnostic analysis systems, nucleic acid testing platforms, genetic analysis systems, pathogen detection solutions, biomarker analysis equipment, automated laboratory testing systems, and precision medicine support technologies. By integrating advanced automation, data management capabilities, and laboratory workflow optimization, BioX Medical develops solutions designed to improve testing efficiency, analytical accuracy, and operational reliability.
Transitioning from relative to absolute quantification. Our next-gen dPCR platforms offer unprecedented sensitivity for rare mutation detection and liquid biopsy applications.
Leveraging machine learning to automate curve analysis and result interpretation, reducing human error and clinical turnaround time (TAT).
Global laboratory connectivity allowing real-time monitoring of thermal cycler performance and seamless data synchronization across borders.
The industry is moving beyond simple detection. Future PCR tools will emphasize "Molecular Intelligence"—the ability of a system to not only amplify DNA but also suggest clinical pathways based on multiplexed data. As a leading exporter, BioX Medical is at the forefront of this shift, ensuring our clients in North America, Europe, and Asia-Pacific have access to Future-Proof Diagnostic Platforms.
Exporting complex medical devices requires more than just manufacturing prowess; it requires deep adherence to international regulatory frameworks. Shenzhen BioX Medical Co., Ltd. ensures that every PCR system and diagnostic tool meets stringent standards, including ISO 13485, CE-IVD, and alignment with FDA requirements for specific markets.
Our global footprint across Europe, Latin America, and Africa is supported by a robust Local Support Infrastructure. We offer:
BioX Medical
